Organic Active Ingredients TRIZ Cases

Pidolate and malate salts use acid addition and co-crystal formation to improve water solubility while limiting degradation and precipitation in injections.

An anti-HBV antibody paired with HBV-targeting siRNA addresses limited HDV efficacy and cirrhosis contraindications by suppressing viral replication.

Amide-substituted heteroaryl compounds inhibit Tyk2-mediated signaling to modulate IL-12, IL-23, and IFNα in autoimmune disease.

Precise PAHG injection into the external urethral sphincter rebuilds the urethral seal for stress urinary incontinence.

Immunostimulatory spherical nucleic acids spatially present oligonucleotides to activate TLR9 while limiting off-target effects and toxicity.

Direct asymmetric oxidation replaces racemic synthesis and chiral separation, delivering the target (S)-enantiomer with 27% overall yield.

Topical MPC-inhibiting compounds increase lactate production in hair follicle stem cells to address inconvenient or invasive baldness treatments.

Blocking hnRNP R binding to MAPT mRNA limits axonal tau transport while preserving somatodendritic tau function.

A modified hyaluronic acid hydrogel stabilizes 9-hydroxycalabaxanthone for prolonged antimicrobial action without chlorhexidine-related tissue toxicity.

Biodegradable PEG gels embed drug-loaded nanoparticles to sustain local antibiotic and analgesic release while limiting systemic side effects.

Formula I compounds inhibit WEE1 kinase activity, using CDK1 phosphorylation and G2/M progression to validate checkpoint targeting.

Targeted S1 and S4 amino acid substitutions lower apixaban affinity while preserving Factor Xa activity for DOAC bleeding reversal.

Modified polymer structures target peripheral NMDARs while limiting BBB and intestinal-barrier crossing and CNS side effects.

Chemical disruption of corneal cell junctions enables riboflavin to reach the stroma within minutes without epithelial removal.

See how Desulfovibrio species and metabolites such as 6-bromotryptophan inhibit NFκB activation to reduce inflammation and support immune modulation.

A modular P1′, P2, and P3 structure targets the SARS-CoV-2 3C-like protease to inhibit replication while managing synthesis complexity.

Controlled-release polymers and cysteine combine in bupropion compositions to address excipient-driven degradation while supporting manufacturability.

Chemical linkage joins sgRNA to a CRISPR effector protein, improving complex stability for precise gene editing.

Glycerin, maltitol, and flavors support palatable Imatinib liquids for consistent dosing when tablets are difficult to swallow.

Self-assembled Janus base nanotubes improve cellular uptake and endosomal escape while limiting cytotoxicity and immunogenicity during biologically active material delivery.

Pan-BET inhibitors risk dose-limiting thrombocytopenia; BRDT-BD1-selective compounds aim to preserve treatment activity while limiting off-target toxicity.

Formula (I) compounds are used orally or by injection to cross the blood-brain barrier and increase brain plasmalogen levels.

New lincosamide derivatives target resistant pathogens while reducing adverse effects on commensal gut flora.

Defined ratios of PEG-modified irinotecan and temozolomide address limited efficacy in neuroblastoma, with inhibition reaching 98% in models.

A plasticizer-free HPMC/HPC film coating helps preserve ibrutinib Form C, improve swallowability, and avoid surfactant-related irritation.

See how a modular PROTAC links cMET and an E3 ligase to trigger polyubiquitination and proteasome degradation.

Novel small molecules target TLR7 to suppress IL-6 and IFN-α, addressing CB-7’s limited potency in autoimmune disease treatment.

Selective EP2 antagonists target prostaglandin E2 signaling to relieve inflammation while limiting off-target effects of nonselective COX inhibition.

Alternative sweeteners and particulate fillers maintain sweetness in oral pouches while avoiding sucralose-related environmental accumulation.

Specific alcohol–polyol solvent ratios help hedgehog inhibitors cross the stratum corneum while limiting systemic absorption for topical basal cell carcinoma treatment.

Limited bioavailability and safety in conventional BTK therapy are addressed through ring-derivative compounds that inhibit or degrade BTK.

Levodopa may improve motor symptoms while mood worsens as it clears; NMN derivatives support sustained relief in parkinsonism.

Overlapping 5-30-residue peptides cover a target protein to induce antibodies without carrier proteins, reducing side effects and production costs.

Aminoguanidine hydrazone derivatives target the VPS35-VPS29 interface to stabilize retromer function and reduce Aβ40/Aβ42 accumulation.

Limited KIF18A inhibitor variety is addressed with related spirocyclic series that maintain inhibitory activity and induce mitotic arrest in cancer cells.

Oxadiazole modification preserves α2A-AR antagonist activity while reducing brain distribution and central anxiety or hypertension.

Recognizing biotin’s valeric acid moiety helps the antibody reduce interference from high biotin levels without binding biotinylated molecules.

Formula I compounds invert conventional PPARG activation by stabilizing the target in an inactive state for urothelial cancer treatment.

Existing FAK inhibitor formulations may lack crystallinity, stability, and solubility; a crystalline tartrate form addresses these limits.

A modular c-MET PROTAC separates protein binding, E3 ligase recruitment, and linker functions to enable targeted degradation.

To address slow healing in elderly tissue, the cation and its salts reduce oxidative stress and promote cell proliferation.

Piperine inhibits p-glycoprotein efflux, helping active ingredients cross the blood-brain barrier in liquid or chewable oral products.

See how sequential decitabine and MPS1 inhibition reverses STING silencing and improves T-cell infiltration in KL mutant lung cancer.

Alpha-lipoic acid in fish and shrimp feed improves FCR and weight gain while modulating gut flora and reducing mortality.

Complementary antisense binding suppresses LPA RNA, while asymmetric strands help preserve inhibition efficacy and limit off-target activity.

NKG2D ligands and IL-18 guide corticosteroid or TNFα inhibitor selection for ICI-colitis, limiting prolonged immune suppression.

See how ibudilast and bumetanide target inflammation in ASD patients with NF-κB overactivation for more focused treatment.

Modified indolyl butanenitrile compounds inhibit replication across SARS-CoV-2, MERS-CoV, and SARS-CoV with minimal cytotoxicity.

ANA disaggregates amyloid-beta plaques at low concentrations, while a porous silicon platform targets the brain and limits toxicity.

Combining NMN with PQQ, coenzyme Q10, ginsenoside, and aminobutyric acid addresses weak resistance and inflammation symptoms.

Combining DHA, ARA, iron, vitamin B12, and phospholipids reduces night awakenings and increases day sleep duration in infants.

Simultaneous polysaccharide substitution and crosslinking via hydroxyl functions avoids competition between reaction species, maintaining polymer integrity.

Form L nilotinib hydrochloride achieves improved chemical purity, solubility, and stability through controlled crystallization in formic acid and ethylformate.

Merging dopaminergic and analgesic agents prevents the transition from acute to chronic pain by normalizing synaptic connectivity.

Maltodextrin masks salty taste in dry colon cleansing compositions, maintaining free-flowing stability for 24 months.

Antibodies targeting ASC inhibit inflammasome assembly, reducing chronic neuroinflammation in Alzheimer's disease.

Composite cationic and neutral lipids resolve low transfection efficiency in primary cells by enhancing membrane fusion.

Slurrying the salt in isopropyl acetate and water removes methyl bromide contamination to yield high purity Form D crystals.

Nonsteroidal tricyclic ligands block the mineralocorticoid receptor while avoiding hERG channel blockade and hyperkalemia risks found in steroid-based drugs.

Benzodiazepine derivatives selectively bind to GABAA gamma1 receptors to increase chloride influx, resolving side effects from non-selective modulation.

Artemin pathway inhibitors block tumor survival signals to enhance anti-tumor immune responses.

Carboxymethoxy beta-carboline derivatives act as multi-functional agents targeting insulin resistance and lipid accumulation.

Segmented synthesis of pyrazole amides optimizes receptor antagonism, resolving ATP interference for effective therapeutic outcomes.

Phosphonate-containing nucleotide analogues inhibit tumor cell growth and induce apoptosis in cancer treatments.

Branched Y-shaped DNA segments aptamers into a multivalent complex that increases VEGF capture specificity while reducing non-specific toxicity.

Alginate film adheres to oral mucosa and dissolves slowly to release ketamine, ensuring consistent plasma levels without needle-stick injuries.

Esterified pectins with a degree of esterification below 65% bind Toll-like receptor 2 to reduce inflammatory responses without surgical invasiveness.

Venetoclax treatment increases T cell-mediated cytotoxicity through activation marker upregulation.

Administering NMDA receptor modulating compounds normalizes sterol levels and improves brain excitability to treat Smith-Lemli-Opitz syndrome.

Optimized molecular structures extend plasma half-life and reduce toxicity while maintaining potent BTK inhibition.

N-undecylenoyl phenylalanine polyol esters compete with alpha-MSH hormone for receptor binding to inhibit melanin production.

5-substituted difluoropiperidine derivatives overcome blood-brain barrier limitations by inhibiting VEGFR2 and FYN kinases.

A prebiotic composition containing Musa ferment promotes Akkermansia muciniphila proliferation in the intestine.

Pairing bromodomain and extra-terminal protein inhibitors with chemotherapy overcomes resistance pathways while minimizing side effects.

Replacing high-GWP propellants with 1,1-difluoroethane eliminates nozzle blockage and throat irritancy caused by ethanol while maintaining drug solubility.

ABX196 activates NKT cells to reduce bladder tumor volume without complex combination chemotherapy regimens.

An oral composition combining branched-chain amino acids with coenzyme Q10, L-carnitine, citric acid, and zinc to enhance energy production.

Antisense oligonucleotides bind transposable element RNA transcripts to inhibit expression, resolving detection accuracy limits in complex genomic regions.

Heterocyclic compounds inhibit glutaminase to disrupt tumor energy and nitrogen metabolism.

Hemisulfate and meglumine salt forms stabilize PPARδ agonists via controlled crystallization, resolving manufacturing complexity trade-offs.

A nanoemulsion formulation dissolves hydrophobic compounds in non-polar media suspended in water.

Zirconium chloride catalyzes isohexide acylation, achieving 5:1 exo over endo selectivity while suppressing color development.

Converting gemfibrozil to a salt form resolves poor aqueous solubility, enabling rapid dissolution and improved bioavailability in artificial saliva.

Non-aqueous lipid carriers solubilize triazoloquinazolinone compounds via phospholipids, improving bioavailability while avoiding benzodiazepine side effects.

Alkaloid aminoester derivatives deliver localized bronchodilation while minimizing systemic side effects via rapid plasma hydrolysis into inactive metabolites.

Self-assembling steroid dimers form fibrous articles releasing drugs via surface erosion, eliminating burst release and carrier-related side effects.

A multi-nutrient composition containing protein, creatine, vitamin D, calcium, and n-3 fatty acids enhances muscle strength and lean mass.

Pyrimidine-diamine compounds target cytosolic Hsp90 and mitochondrial TRAP1 to overcome blood-brain barrier limitations in glioblastoma treatment.

Antisense oligomers block aberrant splicing of NMD-inducing exons in OPA1 pre-mRNA, restoring functional protein levels to address mitochondrial deficits.

Phenyl-substituted dihydronaphthyridine compounds antagonize the mineralocorticoid receptor to treat cardiovascular diseases.

Antibody-drug conjugates targeting adrenergic receptors reduce abnormal PBMC counts in leukemia patients while overcoming drug resistance.

Oral benzimidazole compounds replace injectable antibodies to treat inflammatory diseases while lowering treatment costs.

Intradermal threading delivers antisense oligonucleotides that inhibit CTGF expression, reducing recurrence rates in hypertrophic scar treatment.

Liposomal bioactive lipid compositions encapsulate hydrocarbon-derivatized fatty acids to enhance cellular uptake and therapeutic delivery.